Back Sheridan, C (14 April 2025) 'Not just obesity: GLP-1 receptor agonists advance on addiction', Nature Biotechnology , 43, 455-47.Back Sims, EK, Carr, ALJ, Oram, RA, et al (15 July 2022) '100 years of insulin: celebrating the past, present and future of diabetes therapy', Nature Medicine , 27/7, 1154-64
Following tests in animals, Amylin launched trials of its new synthetic version of exendin-4 in humans
Understanding which GLP-1 mechanism may fit your metabolic profileinformed by biomarkers or genetic predispositions in peptide pathwayscan help reduce wasted spending on less-effective protocols and support a more personalized conversation with your healthcare provider
Plaintiffs argue that mounting medical evidence about gastroparesis, intestinal obstruction, and NAION vision loss should have prompted immediate and comprehensive warning label updates not the reactive, incremental modifications that only occurred after thousands of patients suffered these exact injuries